Research

Hormonal

GLP-1 receptor agonists (GLP-1RAs) exert anti-inflammatory effects by suppressing pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β) and inhibiting the NF-κB pathway, independent of glycemic control.

GLP-1 medications like semaglutide and liraglutide do more than just lower blood sugar; they actively reduce systemic inflammation by blocking key inflammatory pathways (NF-κB) and lowering pro-inflammatory cytokines. This benefit exists regardless of whether your blood sugar improves, suggesting these drugs may help with inflammatory conditions beyond diabetes.

GoodSupportsHIGH confidence
GLP-1RA has been demonstrated to reduce the generation of inflammatory mediators by inhibiting NF-κB activation... GLP-1RAs can boost the generation of anti-inflammatory cytokines such as IL-10, which helps to mitigate inflammation and restore immune balance.
Saleh Hadi Alharbi · Therapeutic Advances in Endocrinology and Metabolism · 2024

Why this rating

The paper is a review citing multiple preclinical and clinical studies, but lacks a single definitive large-scale RCT for inflammation endpoints in non-diabetic populations.

Source

Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications

Saleh Hadi Alharbi · Therapeutic Advances in Endocrinology and Metabolism · 2024

DOI 10.1177/20420188231222367

narrative_reviewCited 271×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →